SecBot SecBot
144 ·Filed Mar 31, 2026

KROS

Keros Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago SEC0000947871-26-000370
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

Monitor for actual sales in upcoming days via Form 4 filings; while the volume is small and seller is a long-term institutional holder, any execution could add minor near-term selling pressure. No immediate catalyst or fundamental change implied.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.69
T+0 close · Mar 31, 2026 · via day close
Latest settled
−6.50%
T+60 · $10.93
Vs SPY
−19.88%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 1 $11.69entry
  2. T+1 · 8mo ago +2.65%α +2.57% · $12.00
  3. T+5 · 7mo ago +6.84%α +3.08% · $12.49
  4. T+20 · 7mo ago −5.05%α −14.77% · $11.10
  5. T+60 · 5mo ago −6.50%α −19.88% · $10.93
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

OrbiMed Advisors LLC, on behalf of its affiliate OrbiMed Genesis Master Fund, LP, has filed a Form 144 to notify intent to sell up to 45,057 shares of Keros Therapeutics (KROS) common stock. The shares were acquired in connection with KROS's IPO on April 13, 2020, and are now eligible for sale under Rule 144.

Key Facts

  • Reporting entity: OrbiMed Advisors LLC, acting for OrbiMed Genesis Master Fund, LP
  • Number of shares proposed for sale: 45,057
  • Shares acquired: April 13, 2020 (IPO date)
  • Filing date: March 31, 2026
  • Shares to be sold: Common stock of Keros Therapeutics, Inc. (KROS)
  • Broker: Themis Trading LLC
  • Market: Nasdaq Stock Market

Financial Impact

Approximately $2.2 million based on current market price (~$49 per share), representing a small fraction of KROS's $218M market cap

insider ownershippotential near-term supply

Risk Factors

  • Potential for increased near-term selling pressure if sale is executed rapidly
  • Signal of reduced conviction by a long-standing institutional investor

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0000947871-26-000370
Document: 0000947871-26-000370-index.html0000947871-26-000370
Document: 0000947871-26-000370.txt0000947871-26-000370

Track record

27 reports on KROS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
  3. Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  5. Nov 5, 202611d ago Press Release Neutral 5/10 No price data
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
  7. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
  8. Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  9. Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  10. Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 6h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 31, 2026